Zimbabwe has declined a significant American health deal worth $367m (£272m) spanning five years because of Washington's request for sensitive biological samples.
This move was revealed following a official document dated December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesman has since explained that the United States was seeking health data for scientific study and commercial gain while was not willing to guarantee the benefits from future vaccines.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more talks to reach a deal acceptable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a comparable situation in Kenya, where a court halted a related deal with the US following concerns were filed about the safety of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral deals to boost transparency and accountability.
Based on reports, 16 nations in Africa have so far signed similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Effectively, our nation would provide the basic resources for medical research without any assurance that the end products would be available to our people should a future pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending structures already established through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a country provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent collaboration might be arranged in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
Medical experts expressed it recognised the government's concerns, but suggested that negotiations must proceed given that much of the nation's Aids initiatives depended on foreign aid.
"If technical issues exist, including those involving information security or implementation frameworks, these can frequently be addressed via detailed discussion and negotiated safeguards," the group commented.
The halted deal emphasises the ongoing debate between receiving vital international aid and protecting a country's data in an increasingly data-driven world.